Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 4

1(33.3%)

3Total

N/A(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials

NCT04398030Not ApplicableCompleted

Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")

Role: collaborator

NCT02345967Not ApplicableCompleted

Function of Implanted Glucose Sensor 2

Role: collaborator

NCT02789319Phase 4Completed

DTS Blood Glucose Monitor System Surveillance Program SubStudy 1

Role: collaborator

All 3 trials loaded